INS and metabolic syndrome: The findings of this randomized, placebo-controlled trial suggest a significant amelioration of dyslipidemia and insulin sensitivity after 90 days of BPE-C supplementation to a group of MetS patients characterized by an elevated AIP (over 0.34) and moderate hyperglycemia (up to 130 mg/L).